Sprout's old CEO is back, and she's got some new marketing ideas for female libido drug Addyi

Now that former shareholders of Sprout Pharmaceuticals, maker of controversial female libido pill Addyi, have the company back in their hands, they’ve reinstalled a familiar face at the helm. Cindy Eckert, who went by Cindy Whitehead during her last stint as CEO, is once again in the company’s top spot, Fortune reported. She vacated that position after Valeant bought Sprout back in 2015, a deal the serial buyer announced just one day after Eckert and co. snagged a third-try FDA approval for Addyi. This time, she’ll be overseeing the launch of the drug herself—and the rollout will look very different than Valeant’s did. For one, Sprout will use a telehealth model to sell the therapy; doctors will be able to diagnose patients and prescribe the drug through the web, Bloomberg reported. Sprout will also sell the drug for $400, half the price Valeant slapped on it not long before the company was derailed by allegations related to specialty pharmacy Philidor. Those ultimately resulted in multibillion-dollar kickback charges against executives from both companies.